Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.
Identifieur interne : 000265 ( Main/Exploration ); précédent : 000264; suivant : 000266Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.
Auteurs : Silvia Jiménez-Jorge [Espagne] ; Salvador De Mateo ; Concha Delgado-Sanz ; Francisco Pozo ; Inmaculada Casas ; Manuel Garcia-Cenoz ; Jesús Castilla ; Esteban Pérez ; Virtudes Gallardo ; Carolina Rodriguez ; Tomás Vega ; Carmen Qui Ones ; Eva Martínez ; Juana María Vanrell ; Jaume Giménez ; Daniel Castrillejo ; María Del Carmen Serrano ; Julián Mauro Ramos ; Amparo LarrauriSource :
- BMC infectious diseases [ 1471-2334 ] ; 2013.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte d'âge moyen (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Phylogenèse (MeSH), Saisons (MeSH), Sous-type H3N2 du virus de la grippe A (classification), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (isolement et purification), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Surveillance sentinelle (MeSH), Vaccination (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie), Virus de la grippe A (génétique), Virus de la grippe A (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Virus de la grippe A.
- immunologie : Grippe humaine, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Virus de la grippe A.
- isolement et purification : Sous-type H3N2 du virus de la grippe A.
- prévention et contrôle : Grippe humaine.
- virologie : Grippe humaine.
- épidémiologie : Espagne, Sous-type H3N2 du virus de la grippe A.
- Adolescent, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Phylogenèse, Saisons, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance sentinelle, Vaccination.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Humans (MeSH), Infant (MeSH), Influenza A Virus, H3N2 Subtype (classification), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (immunology), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza A virus (genetics), Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Phylogeny (MeSH), Seasons (MeSH), Sentinel Surveillance (MeSH), Spain (epidemiology), Vaccination (MeSH), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : Spain.
- classification : Influenza A Virus, H3N2 Subtype.
- genetics : Influenza A Virus, H3N2 Subtype, Influenza A virus, Influenza Vaccines.
- immunology : Influenza A Virus, H3N2 Subtype, Influenza A virus, Influenza Vaccines, Influenza, Human.
- isolation & purification : Influenza A Virus, H3N2 Subtype.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Phylogeny, Seasons, Sentinel Surveillance, Vaccination, Young Adult.
Abstract
BACKGROUND
In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System. The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011-2012 season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the epidemic and according to time since vaccination.
METHODS
Medically attended patients with ILI were systematically swabbed to collect information on exposure, laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were swabbed <8 days after symptom onset were included. Cases tested positive for influenza and controls tested negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the phase of the season and according to the time between vaccination and symptoms onset.
RESULTS
The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0-69). The estimated influenza VE was 52% (95% CI, -3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135 to 74) at 3.5 months, 3.5-4 months, and >4 months, respectively, since vaccination. A decrease in VE with time since vaccination was only observed in individuals aged ≥ 65 years. Regarding the phase of the season, decreasing point estimates were only observed in the early phase, whereas very low or null estimates were obtained in the late phase for the shortest time interval.
CONCLUSIONS
The 2011-2012 influenza vaccine showed a low-to-moderate protective effect against medically attended, laboratory-confirmed influenza in the target groups for vaccination, in a late season and with a limited match between the vaccine and circulating strains. The suggested decrease in influenza VE with time since vaccination was mostly observed in the elderly population. The decreasing protective effect of the vaccine in the late part of the season could be related to waning vaccine protection because no viral changes were identified throughout the season.
DOI: 10.1186/1471-2334-13-441
PubMed: 24053661
PubMed Central: PMC3848794
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.</title><author><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name><affiliation wicri:level="2"><nlm:affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no, 5, Madrid 28029, Spain. sjimenezj@isciii.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no, 5, Madrid 28029</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="De Mateo, Salvador" sort="De Mateo, Salvador" uniqKey="De Mateo S" first="Salvador" last="De Mateo">Salvador De Mateo</name></author><author><name sortKey="Delgado Sanz, Concha" sort="Delgado Sanz, Concha" uniqKey="Delgado Sanz C" first="Concha" last="Delgado-Sanz">Concha Delgado-Sanz</name></author><author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name></author><author><name sortKey="Casas, Inmaculada" sort="Casas, Inmaculada" uniqKey="Casas I" first="Inmaculada" last="Casas">Inmaculada Casas</name></author><author><name sortKey="Garcia Cenoz, Manuel" sort="Garcia Cenoz, Manuel" uniqKey="Garcia Cenoz M" first="Manuel" last="Garcia-Cenoz">Manuel Garcia-Cenoz</name></author><author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name></author><author><name sortKey="Perez, Esteban" sort="Perez, Esteban" uniqKey="Perez E" first="Esteban" last="Pérez">Esteban Pérez</name></author><author><name sortKey="Gallardo, Virtudes" sort="Gallardo, Virtudes" uniqKey="Gallardo V" first="Virtudes" last="Gallardo">Virtudes Gallardo</name></author><author><name sortKey="Rodriguez, Carolina" sort="Rodriguez, Carolina" uniqKey="Rodriguez C" first="Carolina" last="Rodriguez">Carolina Rodriguez</name></author><author><name sortKey="Vega, Tomas" sort="Vega, Tomas" uniqKey="Vega T" first="Tomás" last="Vega">Tomás Vega</name></author><author><name sortKey="Qui Ones, Carmen" sort="Qui Ones, Carmen" uniqKey="Qui Ones C" first="Carmen" last="Qui Ones">Carmen Qui Ones</name></author><author><name sortKey="Martinez, Eva" sort="Martinez, Eva" uniqKey="Martinez E" first="Eva" last="Martínez">Eva Martínez</name></author><author><name sortKey="Vanrell, Juana Maria" sort="Vanrell, Juana Maria" uniqKey="Vanrell J" first="Juana María" last="Vanrell">Juana María Vanrell</name></author><author><name sortKey="Gimenez, Jaume" sort="Gimenez, Jaume" uniqKey="Gimenez J" first="Jaume" last="Giménez">Jaume Giménez</name></author><author><name sortKey="Castrillejo, Daniel" sort="Castrillejo, Daniel" uniqKey="Castrillejo D" first="Daniel" last="Castrillejo">Daniel Castrillejo</name></author><author><name sortKey="Serrano, Maria Del Carmen" sort="Serrano, Maria Del Carmen" uniqKey="Serrano M" first="María Del Carmen" last="Serrano">María Del Carmen Serrano</name></author><author><name sortKey="Ramos, Julian Mauro" sort="Ramos, Julian Mauro" uniqKey="Ramos J" first="Julián Mauro" last="Ramos">Julián Mauro Ramos</name></author><author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24053661</idno><idno type="pmid">24053661</idno><idno type="doi">10.1186/1471-2334-13-441</idno><idno type="pmc">PMC3848794</idno><idno type="wicri:Area/Main/Corpus">00230</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00230</idno><idno type="wicri:Area/Main/Curation">000230</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000230</idno><idno type="wicri:Area/Main/Exploration">000230</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.</title><author><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name><affiliation wicri:level="2"><nlm:affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no, 5, Madrid 28029, Spain. sjimenezj@isciii.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no, 5, Madrid 28029</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="De Mateo, Salvador" sort="De Mateo, Salvador" uniqKey="De Mateo S" first="Salvador" last="De Mateo">Salvador De Mateo</name></author><author><name sortKey="Delgado Sanz, Concha" sort="Delgado Sanz, Concha" uniqKey="Delgado Sanz C" first="Concha" last="Delgado-Sanz">Concha Delgado-Sanz</name></author><author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name></author><author><name sortKey="Casas, Inmaculada" sort="Casas, Inmaculada" uniqKey="Casas I" first="Inmaculada" last="Casas">Inmaculada Casas</name></author><author><name sortKey="Garcia Cenoz, Manuel" sort="Garcia Cenoz, Manuel" uniqKey="Garcia Cenoz M" first="Manuel" last="Garcia-Cenoz">Manuel Garcia-Cenoz</name></author><author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name></author><author><name sortKey="Perez, Esteban" sort="Perez, Esteban" uniqKey="Perez E" first="Esteban" last="Pérez">Esteban Pérez</name></author><author><name sortKey="Gallardo, Virtudes" sort="Gallardo, Virtudes" uniqKey="Gallardo V" first="Virtudes" last="Gallardo">Virtudes Gallardo</name></author><author><name sortKey="Rodriguez, Carolina" sort="Rodriguez, Carolina" uniqKey="Rodriguez C" first="Carolina" last="Rodriguez">Carolina Rodriguez</name></author><author><name sortKey="Vega, Tomas" sort="Vega, Tomas" uniqKey="Vega T" first="Tomás" last="Vega">Tomás Vega</name></author><author><name sortKey="Qui Ones, Carmen" sort="Qui Ones, Carmen" uniqKey="Qui Ones C" first="Carmen" last="Qui Ones">Carmen Qui Ones</name></author><author><name sortKey="Martinez, Eva" sort="Martinez, Eva" uniqKey="Martinez E" first="Eva" last="Martínez">Eva Martínez</name></author><author><name sortKey="Vanrell, Juana Maria" sort="Vanrell, Juana Maria" uniqKey="Vanrell J" first="Juana María" last="Vanrell">Juana María Vanrell</name></author><author><name sortKey="Gimenez, Jaume" sort="Gimenez, Jaume" uniqKey="Gimenez J" first="Jaume" last="Giménez">Jaume Giménez</name></author><author><name sortKey="Castrillejo, Daniel" sort="Castrillejo, Daniel" uniqKey="Castrillejo D" first="Daniel" last="Castrillejo">Daniel Castrillejo</name></author><author><name sortKey="Serrano, Maria Del Carmen" sort="Serrano, Maria Del Carmen" uniqKey="Serrano M" first="María Del Carmen" last="Serrano">María Del Carmen Serrano</name></author><author><name sortKey="Ramos, Julian Mauro" sort="Ramos, Julian Mauro" uniqKey="Ramos J" first="Julián Mauro" last="Ramos">Julián Mauro Ramos</name></author><author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza A Virus, H3N2 Subtype (classification)</term><term>Influenza A Virus, H3N2 Subtype (genetics)</term><term>Influenza A Virus, H3N2 Subtype (immunology)</term><term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term><term>Influenza A virus (genetics)</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (genetics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Phylogeny (MeSH)</term><term>Seasons (MeSH)</term><term>Sentinel Surveillance (MeSH)</term><term>Spain (epidemiology)</term><term>Vaccination (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (virologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Phylogenèse (MeSH)</term><term>Saisons (MeSH)</term><term>Sous-type H3N2 du virus de la grippe A (classification)</term><term>Sous-type H3N2 du virus de la grippe A (génétique)</term><term>Sous-type H3N2 du virus de la grippe A (immunologie)</term><term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Surveillance sentinelle (MeSH)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (génétique)</term><term>Vaccins antigrippaux (immunologie)</term><term>Virus de la grippe A (génétique)</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A virus</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A virus</term><term>Influenza Vaccines</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Sous-type H3N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Phylogeny</term><term>Seasons</term><term>Sentinel Surveillance</term><term>Vaccination</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Phylogenèse</term><term>Saisons</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Surveillance sentinelle</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System. The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011-2012 season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the epidemic and according to time since vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Medically attended patients with ILI were systematically swabbed to collect information on exposure, laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were swabbed <8 days after symptom onset were included. Cases tested positive for influenza and controls tested negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the phase of the season and according to the time between vaccination and symptoms onset.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0-69). The estimated influenza VE was 52% (95% CI, -3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135 to 74) at 3.5 months, 3.5-4 months, and >4 months, respectively, since vaccination. A decrease in VE with time since vaccination was only observed in individuals aged ≥ 65 years. Regarding the phase of the season, decreasing point estimates were only observed in the early phase, whereas very low or null estimates were obtained in the late phase for the shortest time interval.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The 2011-2012 influenza vaccine showed a low-to-moderate protective effect against medically attended, laboratory-confirmed influenza in the target groups for vaccination, in a late season and with a limited match between the vaccine and circulating strains. The suggested decrease in influenza VE with time since vaccination was mostly observed in the elderly population. The decreasing protective effect of the vaccine in the late part of the season could be related to waning vaccine protection because no viral changes were identified throughout the season.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24053661</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2013</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.</ArticleTitle><Pagination><MedlinePgn>441</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2334-13-441</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System. The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011-2012 season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the epidemic and according to time since vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Medically attended patients with ILI were systematically swabbed to collect information on exposure, laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were swabbed <8 days after symptom onset were included. Cases tested positive for influenza and controls tested negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the phase of the season and according to the time between vaccination and symptoms onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0-69). The estimated influenza VE was 52% (95% CI, -3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135 to 74) at 3.5 months, 3.5-4 months, and >4 months, respectively, since vaccination. A decrease in VE with time since vaccination was only observed in individuals aged ≥ 65 years. Regarding the phase of the season, decreasing point estimates were only observed in the early phase, whereas very low or null estimates were obtained in the late phase for the shortest time interval.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The 2011-2012 influenza vaccine showed a low-to-moderate protective effect against medically attended, laboratory-confirmed influenza in the target groups for vaccination, in a late season and with a limited match between the vaccine and circulating strains. The suggested decrease in influenza VE with time since vaccination was mostly observed in the elderly population. The decreasing protective effect of the vaccine in the late part of the season could be related to waning vaccine protection because no viral changes were identified throughout the season.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiménez-Jorge</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no, 5, Madrid 28029, Spain. sjimenezj@isciii.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mateo</LastName><ForeName>Salvador</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Delgado-Sanz</LastName><ForeName>Concha</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pozo</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Cenoz</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Castilla</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Esteban</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Virtudes</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vega</LastName><ForeName>Tomás</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Quiñones</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Martínez</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vanrell</LastName><ForeName>Juana María</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Giménez</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Castrillejo</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>María del Carmen</ForeName><Initials>Mdel C</Initials></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Julián Mauro</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Larrauri</LastName><ForeName>Amparo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><CollectiveName>Spanish Influenza Sentinel Surveillance System</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24053661</ArticleId><ArticleId IdType="pii">1471-2334-13-441</ArticleId><ArticleId IdType="doi">10.1186/1471-2334-13-441</ArticleId><ArticleId IdType="pmc">PMC3848794</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wkly Epidemiol Rec. 2012 May 25;87(21):201-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24340402</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2008 Apr 18;57(15):393-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18418344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2012 Jun 15;87(24):233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22715518</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2011;11:170</Citation><ArticleIdList><ArticleId IdType="pubmed">21669006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):159-67</Citation><ArticleIdList><ArticleId IdType="pubmed">19086915</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2011;11:899</Citation><ArticleIdList><ArticleId IdType="pubmed">22129083</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):168-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19086914</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 1996 May;3(3):361-2</Citation><ArticleIdList><ArticleId IdType="pubmed">8705685</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1989 Oct;7(5):385-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2683459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):5-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22032845</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012;17(12). pii: 20129</Citation><ArticleIdList><ArticleId IdType="pubmed">22490308</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010;15(44). pii: 19700</Citation><ArticleIdList><ArticleId IdType="pubmed">21087586</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Apr 19;31(17):2165-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23499601</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013;18(5). pii: 20390</Citation><ArticleIdList><ArticleId IdType="pubmed">23399425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>Gac Sanit. 2011 Jan-Feb;25(1):23-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21334788</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(11):e27622</Citation><ArticleIdList><ArticleId IdType="pubmed">22110695</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2011;16(11). pii: 19821</Citation><ArticleIdList><ArticleId IdType="pubmed">21435331</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2011;16(11). pii: 19820</Citation><ArticleIdList><ArticleId IdType="pubmed">21435330</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Dis. 2012 Feb;3(1):68-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22500272</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2011;16(6). pii: 19791</Citation><ArticleIdList><ArticleId IdType="pubmed">21329644</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1994 Oct;12(13):1185-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7839722</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012 Apr 12;17(15). pii: 20146</Citation><ArticleIdList><ArticleId IdType="pubmed">22516046</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(3):e5079</Citation><ArticleIdList><ArticleId IdType="pubmed">19333374</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2003 May;23(3):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12797543</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2008 Oct 23;13(43). pii: 19015</Citation><ArticleIdList><ArticleId IdType="pubmed">18947520</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 2007 Jun;36(3):623-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17403908</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 May 21;30(24):3595-602</Citation><ArticleIdList><ArticleId IdType="pubmed">22472792</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Jun 26;31(30):3104-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23624093</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Apr 1;28(16):2903-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20153351</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012;17(11). pii: 20115</Citation><ArticleIdList><ArticleId IdType="pubmed">22449867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Jan;13(1):7-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23257219</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Apr 12;25(15):2842-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17081662</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2011;16(7). pii: 19799</Citation><ArticleIdList><ArticleId IdType="pubmed">21345321</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013;18(5). pii: 20388</Citation><ArticleIdList><ArticleId IdType="pubmed">23399423</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013;18(5). pii: 20389</Citation><ArticleIdList><ArticleId IdType="pubmed">23399424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Feb 15;197(4):490-502</Citation><ArticleIdList><ArticleId IdType="pubmed">18275271</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Sep 28;25(39-40):6852-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17719149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2010 Dec;64(12):1062-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19910645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region></list><tree><noCountry><name sortKey="Casas, Inmaculada" sort="Casas, Inmaculada" uniqKey="Casas I" first="Inmaculada" last="Casas">Inmaculada Casas</name><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name><name sortKey="Castrillejo, Daniel" sort="Castrillejo, Daniel" uniqKey="Castrillejo D" first="Daniel" last="Castrillejo">Daniel Castrillejo</name><name sortKey="De Mateo, Salvador" sort="De Mateo, Salvador" uniqKey="De Mateo S" first="Salvador" last="De Mateo">Salvador De Mateo</name><name sortKey="Delgado Sanz, Concha" sort="Delgado Sanz, Concha" uniqKey="Delgado Sanz C" first="Concha" last="Delgado-Sanz">Concha Delgado-Sanz</name><name sortKey="Gallardo, Virtudes" sort="Gallardo, Virtudes" uniqKey="Gallardo V" first="Virtudes" last="Gallardo">Virtudes Gallardo</name><name sortKey="Garcia Cenoz, Manuel" sort="Garcia Cenoz, Manuel" uniqKey="Garcia Cenoz M" first="Manuel" last="Garcia-Cenoz">Manuel Garcia-Cenoz</name><name sortKey="Gimenez, Jaume" sort="Gimenez, Jaume" uniqKey="Gimenez J" first="Jaume" last="Giménez">Jaume Giménez</name><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name><name sortKey="Martinez, Eva" sort="Martinez, Eva" uniqKey="Martinez E" first="Eva" last="Martínez">Eva Martínez</name><name sortKey="Perez, Esteban" sort="Perez, Esteban" uniqKey="Perez E" first="Esteban" last="Pérez">Esteban Pérez</name><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name><name sortKey="Qui Ones, Carmen" sort="Qui Ones, Carmen" uniqKey="Qui Ones C" first="Carmen" last="Qui Ones">Carmen Qui Ones</name><name sortKey="Ramos, Julian Mauro" sort="Ramos, Julian Mauro" uniqKey="Ramos J" first="Julián Mauro" last="Ramos">Julián Mauro Ramos</name><name sortKey="Rodriguez, Carolina" sort="Rodriguez, Carolina" uniqKey="Rodriguez C" first="Carolina" last="Rodriguez">Carolina Rodriguez</name><name sortKey="Serrano, Maria Del Carmen" sort="Serrano, Maria Del Carmen" uniqKey="Serrano M" first="María Del Carmen" last="Serrano">María Del Carmen Serrano</name><name sortKey="Vanrell, Juana Maria" sort="Vanrell, Juana Maria" uniqKey="Vanrell J" first="Juana María" last="Vanrell">Juana María Vanrell</name><name sortKey="Vega, Tomas" sort="Vega, Tomas" uniqKey="Vega T" first="Tomás" last="Vega">Tomás Vega</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000265 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000265 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24053661
|texte= Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24053661" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |